

1 Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during
2 pregnancy and early infancy

3

4 Mary Prah, M.D., Yarden Golan, Ph.D., Arianna G. Cassidy, M.D., Yusuke Matsui M.D., Ph.D.,
5 Lin Li, M.D., PhD, Bonny Alvarenga, Hao Chen, Ph.D., Unurzul Jigmeddagva, M.D., Christine Y.
6 Lin, Veronica J. Gonzalez, M.D, Megan A. Chidboy, Lakshmi Warriar, Sirirak Buarpong, D.V.M.,
7 Ph.D., Amy P. Murtha M.D., Valerie J. Flaherman, M.D., M.P.H., Warner C. Greene M.D.,
8 Ph.D., Alan H.B. Wu, Ph.D., Kara L. Lynch Ph.D., Jayant Rajan, M.D., Ph.D., Stephanie L. Gaw,
9 M.D., Ph.D

10

11 Author Affiliations

12 From the Department of Pediatrics, University of California, San Francisco (M.P., V.J.F.),
13 Division of Pediatric Infectious Diseases and Global Health, University of California, San
14 Francisco (M.P.), Department of Bioengineering and Therapeutic Sciences, University of
15 California, San Francisco (Y.G.), Department of Medicine, University of California, San
16 Francisco (L.W., B.A., J.R.), Weill Institute for Neurosciences, Division of Neurology, University
17 of California, San Francisco, CA (B.A.), Gladstone Center for HIV Cure Research, Gladstone
18 Institute, San Francisco, CA (Y.M., W.C.G.) Departments of Medicine and Microbiology and
19 Immunology, University of California, San Francisco (W.C.G.), Department of Laboratory
20 Medicine, University of California, San Francisco (A.H.B.W., K.L.L.), Center for Reproductive
21 Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of
22 California San Francisco (A.G.C., L.L., H.C., U.J., C.Y.L., V.J.G., M.A.C., S.B., A.P.M., S.L.G.).

23

24 Co-Corresponding authors: 1) Mary Prah- Division of Pediatric Infectious Diseases and Global
25 Health, Department of Pediatrics, University of California San Francisco, 550 16th St. 4th Floor.
26 San Francisco, CA 94158. Phone (415) 514-0510, Email: mary.prah@ucsf.edu 2) Stephanie L.

27 Gaw-Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and
28 Reproductive Sciences, University of California San Francisco, 513 Parnassus Ave, HSE16,
29 Box 0556, San Francisco, CA 94143. Phone: (415) 476-0535. Email: Stephanie.Gaw@ucsf.edu

30

31 Abstract

32 Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination
33 during pregnancy, and the levels of protection provided to their newborns through placental
34 transfer of antibodies. We evaluated the transplacental transfer of mRNA vaccine products and
35 functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20
36 individuals vaccinated during pregnancy. We found no evidence of mRNA vaccine products in
37 maternal blood, placenta tissue, or cord blood at delivery. However, we found time-dependent
38 efficient transfer of IgG and neutralizing antibodies to the neonate that persisted during early
39 infancy. Additionally, using phage immunoprecipitation sequencing, we found a vaccine-specific
40 signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred
41 during pregnancy. In conclusion, products of mRNA vaccines are not transferred to the fetus
42 during pregnancy, however timing of vaccination during pregnancy is critical to ensure
43 transplacental transfer of protective antibodies during early infancy.

44

45 Keywords

46 SARS-CoV-2, COVID-19, Pregnancy, Vaccine, Antibody, Neonatal Immunity, Neutralizing
47 Antibody, Phage Array, mRNA Vaccination, BNT-162b2, mRNA-1273, Placenta, Cord Blood

48

49 Introduction

50 Growing evidence has shown that pregnant individuals are at higher risk for SARS-CoV-
51 2-related morbidity and mortality¹⁻⁴. Despite this, vaccination uptake by pregnant individuals has
52 been slower than the general population⁵, in part because of maternal concern of adverse

53 effects on the embryo or fetus, even with strong consensus recommendations for COVID-19
54 vaccination prior to or during pregnancy from several medical societies⁶. Pregnant individuals
55 were excluded from initial vaccine trials, and complete data on safety, efficacy, optimal timing of
56 the vaccine in pregnancy, or its impact on the fetus has been delayed⁷, which may impact
57 individual medical decision making. Current COVID-19 vaccines fully approved and under
58 emergency use in the United States include the mRNA vaccines BNT-162b2 and mRNA-1273,
59 which target the SARS-CoV-2 Spike protein and stimulate protective immune responses^{8,9}. In
60 addition to protecting the mother against severe disease, vaccination during pregnancy may
61 protect the newborn through passive transfer of maternal immunoglobulin. SARS-CoV-2
62 infection and vaccination during pregnancy produces an IgG response that is transferred to the
63 fetus¹⁰⁻¹⁶. Evidence of newborn protection might help address maternal concerns about adverse
64 effects. However, detailed studies of the transplacental transfer of vaccine products and
65 vaccine-related antibody dynamics, functional properties, and persistence during infancy of
66 transferred SARS-CoV-2 antibodies are needed to provide such evidence.

67 We examined the transplacental transfer of mRNA vaccine products and humoral
68 responses using samples from pregnant individuals and their infants vaccinated with either
69 BNT-162b2 or mRNA-1273 mRNA vaccine during pregnancy.

70

71 **Results:**

72 **Cohort:** We evaluated 20 pregnant individuals who received COVID-19 mRNA vaccines during
73 pregnancy and their infants. Participants were vaccinated between December 2020 and April
74 2021. Gestational age at first dose ranged from 13 weeks to 40 weeks (mean 31.2, SD 5.9
75 weeks). Nineteen participants delivered live, singleton infants between January 2021 through
76 April 2021 at gestational ages ranging from 37.4 to 41.1 weeks (mean 39.2, SD 1.1 weeks).
77 One participant who was vaccinated at 13 weeks had a termination of pregnancy due to a lethal
78 skeletal dysplasia of genetic etiology at 20.4 weeks. Eight participants received BNT-162b2

79 (Pfizer-BioNTech) and twelve received mRNA-1273 (Moderna) vaccines. Eighteen participants
80 received both vaccine doses prior to delivery, and two participants received the second dose
81 after delivery. The time from first mRNA vaccine dose ranged from 6-97 (mean 51, SD 24.3)
82 days prior to delivery, time from the second dose ranged from 2-75 (mean 32, SD 21.3) days
83 prior to delivery, and in two participants 15 and 21 days after delivery. No participants received
84 a 3rd dose prior to delivery. Infants born to vaccinated mothers were followed up at convenience
85 time points ranging from age 3 weeks to 15 weeks of life (mean 8.3, SD 3.2). Further
86 demographic data is detailed in Table S1.

87

88 **Vaccine mRNA products do not cross the placenta**

89 To determine the transplacental transfer of mRNA vaccine derived products, we
90 examined available maternal blood at delivery, placenta tissue, and cord blood for Spike protein
91 by Western blot and vaccine mRNA by PCR. All available delivery samples (maternal blood,
92 placental tissue, and cord blood) were negative for Spike protein by Western blot (Supp Figure
93 1, Supp Table 3) and did not have detectable levels of vaccine mRNA by PCR (Suppl Table 3).
94 Together, this indicates that products of mRNA vaccination do not reach the fetus after
95 vaccination during pregnancy at readily detectable levels.

96

97 **mRNA vaccination in pregnancy leads to a robust antibody response**

98 Similar to prior studies^{14,15,17}, we found that mRNA vaccination during pregnancy led to
99 an increase in anti-SARS-Cov-2 IgG following dose 1 (n=7, mean 388.6, SD 224.8 RFU) and an
100 even further robust increase after vaccination dose 2 (n=12, mean 3214, SD 1383 RFU). Anti-
101 SARS-CoV-2 IgM (n=7, mean 53.3, SD 50.2 RFU) was detected in two maternal participants
102 following dose 1, but only 1 participant following dose 2 (n=12, mean 23.8, SD 17 RFU, Fig 1).

103

104 **Vaccine induced anti-SARS-CoV-2 IgG and neutralizing antibodies are transplacentally**
105 **transferred**

106 We then evaluated the transplacental transfer of maternally derived anti-SARS-CoV-2
107 IgG antibodies to their infants. Maternal blood at delivery was available in 19/20 participants and
108 cord blood was available in 17/20 participants. Anti-SARS-CoV-2 IgG was detectable in 94.7%
109 (18/19) of maternal blood samples at delivery (mean 3235, range [10, 7811] RFU). Anti-SARS-
110 CoV-2 IgG was detectable in 88.2% (15/17) cord blood samples (mean 2243, range [2, 4959]
111 RFU). One participant received one mRNA vaccine dose 9 days prior to delivery, and both the
112 maternal and cord blood were negative for IgG at the time of delivery. Another participant
113 received two doses of mRNA vaccine (23 and 2 days) prior to delivery and maternal blood was
114 positive at 55 RFU (positive cutoff >50 RFU), however cord blood IgG was negative (Figure 2A).
115 Maternal and cord blood anti-SARS-CoV-2 IgG levels were moderately correlated, but not
116 statistically significant ($p=0.074$, $R_s=0.446$, Fig 2A). All cord blood samples were anti-SARS-
117 CoV-2 IgM negative.

118 We next evaluated the transplacental transfer of neutralizing antibody titers by a label-
119 free surrogate neutralization assay (sVNT) from mother to cord blood. Maternal and cord blood
120 at delivery had robust neutralizing responses (maternal $n=17$, mean 220.2, range [0, 422]. Cord
121 blood $n=16$, mean 296.6, range [0, 485], Fig 2B). All mother-infant dyads with positive IgG
122 serology at delivery had detectable transplacental transfer of neutralizing antibodies with the
123 exception of one pair in which the mother was borderline IgG positive at delivery and cord blood
124 was negative, for which both maternal and cord blood were negative for neutralizing titers (Fig
125 2B). However, maternal and cord blood neutralizing titers were not significantly correlated
126 ($p=0.361$, $R_s=-0.244$, Fig 2B). Taken together, this indicates that maternal mRNA vaccination
127 induces functional neutralizing antibodies that are transferred to the infant.

128

129 **Maternally-derived vaccine induced anti-SARS-CoV-2 IgG and neutralizing antibodies**
130 **persist through early infancy**

131 A subset of infants was sampled at convenience timepoints during follow up (infant
132 n=11, weeks of life range [3,15] mean 8.3 weeks). Anti-SARS-CoV-2 IgG levels were positive in
133 81.8% of infants at follow-up (9/11 infants, mean 1290, range [1, 3225] RFU, Fig 2A), with one
134 infant still IgG positive at 12 weeks of age (Fig 2C). The two infants that were IgG negative at
135 follow up were both born to mothers who received only one vaccine dose prior to delivery (6 and
136 9 days, respectively). One of these infants did not have paired maternal or cord blood available
137 at the time of delivery for comparison, and the other was IgG negative in cord blood. Maternal
138 and infant follow-up anti-SARS-CoV-2 IgG levels were not significantly correlated; however,
139 cord blood and infant follow-up IgG levels were significantly associated ($p=0.492$, $R_s=0.249$ and
140 $p=0.021$, $R_s=0.76$, respectively, Fig 2A). All infants were IgM negative at the time of follow up.

141 All infants with available IgG positive samples at follow up had detectable neutralizing
142 titers (n=8, mean 154, range [41-256], Fig 2B). Maternal and infant follow-up neutralizing titers
143 were not significantly correlated, as well as cord and infant follow up neutralizing titers ($p=0.665$,
144 $R_s=-0.191$ and $p=0.662$, $R_s=0.214$, respectively, Fig 2B).

145 To compare the rate of decay of IgG antibody levels in mothers and their infants, we
146 evaluated 5 dyads with paired maternal and infant blood samples on the same day at the time of
147 follow-up (range 3-9 weeks post-delivery). Maternal antibody IgG levels decreased faster in
148 mothers than infants (mean delta -974 RFU and -670 RFU, respectively. Fig 2E) at the follow up
149 timepoint. Taken together this indicates, maternally-derived functional vaccine induced
150 antibodies persist at high levels in newborns through early infancy during a critical time of
151 immune vulnerability and may decay slower than maternal IgG antibodies.

152

153 **Vaccine induced antibody timing and transplacental facilitated transfer**

154 We assessed the relationship of anti-SARS-CoV-2 IgG levels to neutralizing antibody
155 levels. We found a strong correlation between IgG and neutralizing titers in maternal plasma at
156 delivery ($R_s=0.744$, $p=0.0012$) and infant follow up ($R_s=0.738$, $p=0.046$) timepoints, but no
157 significant association between IgG and neutralizing titers in cord blood ($R_s=0.121$, $p=0.656$,
158 Figure 3).

159 We then evaluated the impact of timing of vaccination on maternal antibody levels at
160 delivery. We found no statistically significant correlation between maternal IgG levels at delivery
161 and time since dose 1 ($R_s=-0.335$, $p=0.160$) and gestational age at delivery ($R_s=0.270$, $p=0.265$,
162 Fig 4A,B). This lack of correlation appeared to be driven by two participants that had low or
163 absent levels of antibodies at delivery and received their first dose of vaccine within 30 days of
164 delivery. We then evaluated neutralizing titers in those participants with known detectable IgG
165 levels at delivery and found that maternal neutralizing titers at delivery trended with days since
166 vaccine dose 1 but was not statistically significantly ($R_s=-0.422$, $p=0.093$), and maternal
167 neutralizing titers at delivery was not associated with gestational age at dose 1 ($R_s=0.074$,
168 $p=0.780$). One participant was borderline IgG positive at delivery (vaccinated within 30 days of
169 delivery) and did not have detectable neutralizing titers at delivery (Fig 4C,D).

170 To assess facilitated antibody transfer, we evaluated cord-to-maternal antibody IgG and
171 neutralization titer ratios by time since vaccination and gestational age. We found that IgG ratios
172 were highly correlated with both time since first maternal vaccination dose and gestational age
173 at first dose ($R_s=0.917$, $p<0.0001$ and $R_s=-0.739$, $p=0.002$, respectively. Fig 4E,F). However,
174 neutralization titer cord-to-maternal ratios by time since first vaccination dose and gestational
175 age at first dose were not significantly associated ($R_s=0.366$, $p=0.179$ and $R_s=-0.032$, $p=0.913$,
176 respectively, Figure 4G,H). Together, this may indicate that timing of vaccination in pregnancy is
177 critical for maternal-fetal antibody transfer, and functional neutralizing antibodies are
178 differentially transferred to the fetus as compared to total anti-SARS-CoV-2 IgG during
179 gestation.

180

181 **mRNA vaccination leads to a unique SARS-CoV2 Spike protein antibody epitope binding**
182 **signature**

183 We next investigated antibody linear epitope binding and transplacental transfer using
184 the PhIP-seq/VirScan SARS-CoV-2 Spike protein phage display array in mother-infant dyads at
185 the time of birth (Figure 5). We found that timing of vaccination was important for the trans-
186 placental transfer of Spike protein epitope binding antibodies. Two mother-infant dyads had
187 minimal Spike protein specific epitope binding. The first dyad only received one dose of mRNA
188 vaccine 9 days prior to delivery, and the other dyad received the second vaccine dose 2 days
189 prior to delivery.

190 We found high levels of SARS-CoV-2 Spike protein epitope binding in 4 major peaks we
191 designate as regions 1-4 (Figure 5A). Region 1 overlays the carboxy terminal of the N-terminal
192 domain. Region 2 overlaps with key residues for the S1/S2 cleavage site. Regions 3 and 4 are
193 within S2, flanking the fusion loop and the transmembrane portion of the Spike protein,
194 respectively. However, we found minimal binding in the receptor binding domain (RBD) of Spike
195 protein. Prior evaluation using the PhIP-seq/VirScan SARS-CoV-2 epitope phage array during
196 SARS-CoV-2 infection demonstrated similar binding in regions 3 and 4, however in SARS-CoV-
197 2 infection there was minimal binding in regions 1 and 2 demonstrating that antibody epitope
198 binding in these regions may be unique to vaccination¹⁸. Additionally, there is proportional
199 representation of linear epitope binding across the SARS-CoV-2 Spike protein proteome
200 between mothers and infants (Figure 5B). Taken together, SARS-CoV-2 antibody linear epitope
201 binding after vaccination during pregnancy shows similar patterns, with multiple
202 immunodominant regions found in the majority of mothers and infants. Some of these regions
203 are unique to vaccination and not observed during natural infection¹⁸⁻²⁰.

204

205 **Discussion**

206 Among twenty women who received the COVID-19 mRNA vaccine during pregnancy,
207 our study found no evidence of transplacental transfer of mRNA vaccine products but did find
208 high levels of functional vaccine-derived antibodies that transferred to the infant at delivery and
209 persisted during early infancy. Additionally, we identified high levels of epitope binding in two
210 regions of Spike protein unique to SARS-CoV-2 vaccination¹⁸. These data may address some of
211 the many unanswered questions regarding COVID-19 vaccination in pregnancy: including the
212 dynamics of antibody production in the pregnant immune state, and the optimal timing of
213 immunization in pregnancy to impart passive immunity to the newborn during the vulnerable first
214 few weeks of infancy.

215 Uptake of COVID-19 vaccination in pregnancy has been slow⁵, and reasons for vaccine
216 hesitancy are likely multifactorial — but theoretical concerns that vaccine mRNA could cross the
217 placenta have been raised. We found no evidence of mRNA vaccine products in any of our
218 delivery samples. Additionally, no infants in our study had a fetal immune response to Spike
219 protein as demonstrated by a negative anti-SARS-CoV-2 IgM antibody in cord blood and infant
220 follow up samples. This further supports the lack of transfer of vaccine products, as only IgG is
221 transferred from the mother, and IgM production would indicate an endogenous fetal immune
222 response which has rarely been seen in natural infection with SARS-CoV-2 during pregnancy
223 ^{16,21-23}. This provides additional reassurance that mRNA vaccination is safe during pregnancy.

224 We found that the timing of immunization during pregnancy is important to ensure trans-
225 placental transfer of protective antibodies to the neonate, and during critical windows of immune
226 vulnerability during early infancy. Consistent with prior studies showing robust immune
227 responses to mRNA vaccination^{14,15,17}, we found high levels of IgG after two doses of mRNA
228 vaccine. However, completion of the vaccination series well before delivery was important to
229 ensure transfer of antibodies to the infant. Two mothers only received one vaccine dose prior to
230 delivery and did not transfer antibodies as demonstrated by the lack of antibodies in cord (in one
231 with available cord blood) and in both infants at follow-up. Additionally, neutralizing antibodies

232 were not transferred in a mother who received her second dose of vaccine 2 days prior to
233 delivery. All evaluated mothers who received both doses during pregnancy and with the second
234 dose greater than 9 days prior to delivery transferred IgG and neutralizing antibodies to their
235 infants. Consistent with early studies of antibody transfer after COVID-19 vaccination in
236 pregnancy, most of our participants were vaccinated in the third trimester of pregnancy. Larger
237 studies of individuals vaccinated prior to pregnancy and in the first and second trimester are
238 needed to understand persistence and waning of vaccine-induced immune responses.

239 Additionally, we believe we are the first to report that infants in the first few months of life
240 continued to have maternal vaccine-derived anti-SARS-CoV-2 antibodies that were functional
241 as demonstrated by high levels of neutralizing antibodies presenting infants up to 12 weeks of
242 age. This is consistent with known persistence of maternally-derived antibodies from other
243 vaccinations including pertussis, rubella, varicella²⁴⁻²⁶. Additionally, we have previously found
244 persistence of anti-SARS-CoV-2 IgG antibodies in infants after natural infection up to 6
245 months¹⁶. However, the functional capability of these antibodies as compared to anti-SARS-
246 CoV-2 vaccination-derived antibodies is unknown. Further evaluation of the longitudinal
247 persistence of maternal vaccine-derived antibodies during infancy will be critical to determine
248 optimal timing of COVID-19 vaccination in infancy.

249 Evaluation of paired maternal and baby samples at post-partum follow up timepoints
250 showed a faster decline in maternal IgG antibody levels than infants, suggesting that
251 persistence of maternally-derived antibody may be prolonged for infants. Differences in renal
252 excretion and neonatal Fc receptor (FcRn) expression, which is involved in antibody
253 degradation²⁷ in the infant as compared to adults, could underly these differences and should be
254 explored further.

255 Consistent with observations in non-pregnant adults, we found that IgG levels in mothers
256 at delivery, and at infant follow-up were highly correlated with neutralizing titers²⁸. However,
257 cord blood IgG levels did not correlate with neutralizing titers. Moreover, IgG cord-to-maternal

258 ratios, which represent a proxy of maternal to fetal antibody transfer, were highly correlated with
259 timing of vaccination (gestational age and days since the first dose), but cord-to-maternal
260 neutralizing titer ratios were not significantly associated with time since vaccination nor
261 gestational age. During gestation there is facilitated transfer of maternally derived antibodies
262 through the binding of the neonatal Fc receptor in the syncytiotrophoblast layer²⁹. Differences in
263 glycosylation^{30,31}, FcR/FcRn binding affinity^{17,32}, preferential IgG subclass transfer^{33,34} may be
264 different in functional neutralizing antibodies as compared to total IgG antibody transfer.
265 However, a limitation of this study is the majority of participants were vaccinated in the third
266 trimester. Further investigations on factors that influence the transport of functional antibodies
267 across trimesters are needed to understand antibody dynamics and optimal transfer of
268 protective antibodies to infants.

269 Using a PhIP-seq/VirScan SARS-CoV-2 Spike protein phage array we were able to
270 compare linear epitope antibody binding in mothers and their infants. Consistent with IgG and
271 neutralizing antibody evaluation, timing of vaccination was critical to ensure the transplacental
272 transfer of antibodies to the infant. Additionally, we identified unique regions of antibody epitope
273 binding in our vaccinated cohort that were not identified using the same phage library in a prior
274 evaluation of a cohort of SARS-CoV-2 infected individuals¹⁸. One of these regions included the
275 carboxy terminal of the N-terminal domain, with other work having shown that the N-terminal
276 domain is targeted by neutralizing antibodies against Spike protein³⁵. We did not see significant
277 binding in the receptor binding domain (RBD), which may be attributable to the fact that the
278 phage display library displayed short, linear peptides while antibodies targeting RBD are known
279 to target conformational epitopes. Lastly, we found that the same immunodominant regions
280 targeted by antibodies targeting the Spike protein in both mothers and infants.

281 In summary, this work provides further evidence that mRNA vaccination is safe in
282 pregnancy and demonstrates that it generates time-dependent protective, functional antibody
283 responses in mothers and infants that persist during early infancy.

284

285 **Methods**

286 **Cohort and Sample collection:** The University of California San Francisco (UCSF) institutional
287 review board approved the study (20-32077). Written informed consent was obtained from all
288 participants. We enrolled 20 pregnant individuals who were vaccinated with either BNT-162b2
289 or mRNA-1273 mRNA vaccines. Pregnant individuals were followed through delivery, and their
290 infants were followed up to 12 weeks of life. Maternal blood was collected during pregnancy
291 (pre-vaccine, 3-4 weeks post-dose 1, 4-8 weeks post-dose 2). During delivery, maternal blood,
292 placenta tissue, and cord blood was collected. Infant follow-up blood was collected at
293 convenience timepoints. Whole blood was immediately added to RNeasy in a 1:1.3 ratio.
294 Plasma was isolated from whole blood by centrifugation and immediately cryopreserved. Full-
295 thickness placental biopsy was collected within 1 hour of delivery, washed three times with
296 phosphate buffered saline, and preserved in RNeasy.

297

298 **SARS-CoV-2 plasma serology.** Anti-SARS-CoV-2 plasma IgM and IgG antibodies were
299 measured using the Pylon 3D automated immunoassay system (ET Healthcare, Palo Alto, CA).
300 In brief, quartz glass probes are pre-coated with either affinity purified goat anti Human IgM (IgM
301 capture) or Protein G (IgG capture) are dipped into diluted patient sample. Samples are
302 washed, and then the probe is dipped into the assay reagent containing both biotinylated
303 recombinant spike protein receptor binding domain (RBD) and nucleocapsid protein (NP). After
304 a washing, the probe is incubated with a Cy5-streptavidin (Cy5-SA) polysaccharide conjugate
305 reagent, allowing for cyclic amplification of the fluorescence signal. The background corrected
306 signal is reported as relative fluorescent units (RFU) which is proportional to the amount of
307 specific antibodies in the sample allowing for quantification. Levels of IgM and IgG were
308 considered positive if greater than 50 relative fluorescence units.

309

310 **SARS-CoV-2 neutralizing assay**

311 SARS-CoV-2 antibody neutralization titers were measured using a label-free surrogate
312 neutralization assay (LF-sVNT) previously described²⁸. Briefly, the method measures the
313 binding ability of recombinant RBD (Sino Biological, Wayne, PA) coated onto sensing probes
314 (Gator Bio, Palo Alto, CA) to recombinant ACE2 (Sino Biological, Wayne, PA) after neutralizing
315 RBD with SARS-CoV-2 antibodies in serum. Measurements were done using a thin-film
316 interferometry (TFI) label-free immunoassay analyzer (Gator Bio, Palo Alto, CA). Each serum
317 sample was diluted in a series (1:25, 1:100, 1:250, 1:500, 1:1000, 1:2000) in running buffer
318 (PBS at pH 7.4 with 0.02% Tween 20, 0.2% BSA, and 0.05% NaN₃) for analysis. The first
319 testing cycle for each diluted sample measured the binding ability of RBD to ACE2 with
320 neutralization, and the second cycle provided the full binding ability of RBD without
321 neutralization. In each cycle, the recorded time course of signals, as known as the sensorgram,
322 was recorded. The readout measured the signal increase in RBD-ACE2 complex formation,
323 representing the quantity of RBD-ACE2 complex on the sensing probe. A neutralization rate
324 was calculated as the ratio of the readout in the first cycle to that in the second cycle, presented
325 as a percentage. To obtain the neutralizing antibody titer (IC₅₀) for each serum sample, the
326 neutralization rates were plotted against dilutions, and the points were fitted using a linear
327 interpolation model. The reciprocal of the dilution resulting in a 50% neutralization rate was
328 defined as the neutralizing antibody titer.

329

330 **SARS-CoV-2 Spike protein Western blot.** Maternal blood and cord blood were diluted in
331 RNeasy lysis buffer in 1:1.3 ratio, placenta was preserved in RNeasy lysis buffer. Protein lysates were obtained from
332 samples using RIPA buffer (150 mM NaCl, 25 mM Tris-HCl (pH 7.4), 1% NP-40, 0.5% sodium
333 deoxycholate, 0.1% sodium dodecyl sulfate) containing Halt™ protease inhibitor cocktail
334 (ThermoScientific). Cell Lysates were resolved by SDS/PAGE on a Bis-Tris methane 4–12%
335 polyacrylamide gel and transferred to a nitrocellulose membrane, blocked with 5% skimmed

336 milk diluted in PBS, an incubated overnight at 4°C with anti-SARS-CoV-2 Spike mouse mAb
337 (1A9, GeneTex) or anti-GAPDH rabbit polyclonal antibody (GTX100118, GeneTex) respectively
338 diluted 1:1,000 or 1:5,000 in blocking buffer. The membrane was washed in PBS buffer
339 containing Tween-20 (0.1%) and then incubated for 1 h with horseradish peroxidase-conjugated
340 anti-mouse and anti-rabbit secondary antibody (Jackson ImmunoResearch) diluted respectively
341 1:5,000 and 1:10,000. The membrane was thoroughly washed, and proteins visualized using
342 Immobilon Forte Western HRP substrate (Millipore).

343

344 **SARS-CoV-2 Spike mRNA PCR.** Maternal blood and cord blood were diluted in RNAlater in
345 1:1.3 ratio, placenta was preserved in RNAlater. Tissues were kept at -80°C until analyzed.
346 RNA was isolated from samples using the RNeasy Micro or Mini Kit (Qiagen) according to
347 manufacturer's protocol. RNA concentration was measured using nanodrop and all samples had
348 >30 ng/ul total RNA. 500ng RNA was transcribed into cDNA using qScript cDNA synthesis kit
349 (Quantabio). Primers were design to detect the vaccines mRNA (mRNA-1273 Moderna and
350 BNT162b2 Pfizer-BioNtech) as previously described³⁶. Forward primer:
351 AACGCCACCAACGTGGTCATC. Reverse primer: GTTGTTGGCGCTGCTGTACAC. Primers
352 were shown to detect samples containing as low as 1.5 pg of vaccine using vaccine standard
353 curve (Table S2). QuantaStudio 6 Flex (Applied Biosystems) instrument and SsoFast EvaGreen
354 supermix (Bio-Rad) were used for PCR reaction: 30 second 95°C followed by 40 cycles of 5
355 second 95°C and 20 seconds 60°C. All samples were run in triplicate as 20 µL reactions, and Ct
356 values corresponding to <1.5 pg of vaccine based on standard curve (Table S2) were
357 interpreted as a negative result. For vaccines cDNA standard curves, 10000 pg/µL vaccine
358 mRNA (as cDNA) sample was used for serial dilution in 1:3 ratio, up to 0.06 pg/µL. Two µL of
359 these diluted samples were used in each well to create standard curves.

360

361 **PhIP-Seq/VirScan Coronavirus phage display assay**

362 Immunoprecipitation of phage-bound patient antibodies

363 Maternal plasma at delivery and cord plasma were evaluated by PhIP-Seq/Virscan Coronavirus
364 phage display. Construction of the Coronavirus PhIP-Seq library and detailed methods for
365 immunoprecipitation, sequencing and bioinformatic processing of data are identical to what has
366 previously been described¹⁸. For the purposes of the analysis conducted in this study, analysis
367 was restricted to sero-reactivity against the SARS-CoV-2 Spike protein. As previously
368 described, a total of two rounds of amplification and selection were performed for all PhIP-Seq
369 analyses.

370

371 Next Generation Sequencing library prep

372 Amplicon sequencing library preps were performed using the Labcyte Echo 525 and an Integra
373 Via Flow 96 and were identical to what has previously been described¹⁸. All libraries were
374 pooled by equal volume, cleaned and size selected using Ampure XP beads at 1.0X per
375 manufacturer's protocol. Libraries were quantified by High Sensitivity DNA Qubit and quality-
376 checked by High Sensitivity DNA Bioanalyzer. Sequencing was then performed on a NovaSeq
377 S1 (300 cycle kit with 1.3 billion clusters) aiming for sequencing depths of at least 1 million
378 reads per sample.

379

380 Bioinformatic Analysis of PhIP-Seq Data

381 Sequencing reads were aligned to a reference database of the full viral peptide library using the
382 Bowtie2 aligner. For all VirScan libraries, the null distribution of each peptide's log₁₀(rpK) was
383 modeled using a set of 95 pre-pandemic, healthy control sera. All counts were augmented by 1
384 to avoid zero counts in the healthy control sera samples. Multiple distribution fits were examined
385 for these data, with the Normal distribution showing the best fit. These null distributions were
386 used to calculate p values for the observed log₁₀(rpK) of each peptide within a given sample.
387 The calculated p values were corrected for multiple hypothesis using the Benjamini-Hochberg

388 method. Any peptide with a corrected p value of < 0.001 was considered significantly enriched
389 over the healthy background. To identify regions targeted by host antibodies, all library peptides
390 were aligned to the SARS-CoV-2 reference genome. Using the aligned position of the
391 significantly enriched peptides which aligned full-length against the reference, we determined
392 the proportion of individuals (mothers and infants) that were reactive at each residue of the
393 Spike protein. All plots were generated using the R ggplot2 package.

394

395 **Statistical analysis:**

396 Statistical analyses were performed using PRISM v9.2 (GraphPad), STATA 16 (StataCorp), and
397 R version 3.6.3 and R Studio version 1.1.447. Descriptive statistics include mean, standard
398 deviations, and ranges for continuous variables. The Wilcoxon rank-sum test was used for two-
399 group comparisons of continuous variables including maternal pre- and post-vaccine antibody
400 responses. Associations between continuous variables were assessed using Spearman's rank
401 correlation (R_s) including comparisons between maternal, cord and infant follow-up antibody IgG
402 and neutralizing titer responses, and timing of vaccination. Two-sided p values were calculated
403 for all test statistics, and $p < 0.05$ was considered significant. PhIP-Seq/VirScan bioinformatics as
404 detailed above.

405

406 **Data Availability**

407 The data set generated during and/or analyzed during the current study are available from the
408 corresponding author on reasonable request.

409

410 **Acknowledgements:**

411 M.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino
412 Family Foundation, and UCSF REAC award. Y.G. was supported by the Weizmann Institute of
413 Science -National Postdoctoral Award Program for Advancing Women in Science, and of the

414 International Society for Research in Human Milk and Lactation (ISRHML) Trainee Bridge Fund.
415 Y.M. and W.C.G. were supported by The Roddenberry Foundation. S.L.G. was supported by
416 the National Institutes of Health (NIAID K08AI141728), and the Bill and Melinda Gates
417 Foundation (INV-017035), and a generous gift from the Kryzewski Family.

418

419 We thank all the mothers and infants that participated in this study. We thank Kenneth Scott,
420 BS, RPh, (UCSF Health Pharmacy, University of California, San Francisco) and Hannah J.
421 Jang, PhD, RN, PHN, CNL (UCSF School of Nursing, University of California, San Francisco),
422 for voluntarily providing unused vaccine for this study, and to Dr. Margaret Feeney (University of
423 California, San Francisco) and Dr. Nadav Ahituv (University of California, San Francisco) for
424 support of these experiments.

425

426 **Author contributions:**

427 M.P. Helped conceive and design the project, oversaw recruitment, designed, and performed
428 sample collection, oversaw experiment design, oversaw data analysis, provided funding, and
429 drafted the manuscript.

430 Y.G. Recruited and consented enrollees, oversaw sample collection, designed, performed, and
431 analyzed mRNA PCR experiments, performed data analysis.

432 A.G.C. Recruited and consented enrollees, oversaw sample collection, performed chart review,
433 and helped draft the manuscript.

434 Y.M. Performed and helped design Western blot.

435 L.L. Performed and analyzed mRNA PCR experiments, performed sample collection.

436 B.A. Performed phage immunoprecipitation assays.

437 H.C. and U.J. performed and helped design critical experiments, and data collection.

438 C.Y.L., V.J.L., M.C., L.W., S.B. Performed and coordinated sample collection, and data collection.

439 V.J.F. Helped conceive and coordinate the project.

440 A.P.M. Provide funding.

441 W.C.G. Helped design western blot and oversaw data analysis.

442 A.H.B.W Designed and oversaw all serology experiments.

443 K.L.L. Designed and oversaw all neutralizing antibody experiments.

444 J.R. Designed, analyzed, and oversaw phage immunoprecipitation sequencing assays.

445 S.L.G. conceived and designed the project, oversaw recruitment, oversaw experiment design,

446 oversaw data analysis, provided funding, and helped draft the manuscript.

447 M.P., Y.G., Y.U., L.L., A.H.B.W, W.C.G, K.L.L., and S.L.G verified the underlying data.

448 All authors reviewed and approved the manuscript.

449

450

451

452

453

454

455

456


457

458

459

460

461



462

463 **Figure 1. Anti-SARS-CoV-2 IgG and IgM antibody responses following vaccination**

464 A. Maternal plasma anti-SARS-CoV-2 IgG antibody relative fluorescence units (RFU) levels

465 prior to vaccination (n=4), 3-4 weeks post-dose 1 (n=7), and 4-8 weeks post-dose 2 (n=12). B.

466 Maternal plasma anti-SARS-CoV-2 IgM (RFU) levels prior to vaccination (n=4), 3-4 weeks post-

467 dose 1 (n=7), and 4-8 weeks post-dose 2 (n=12). Wilcoxon rank-sum testing. Data represent

468 median \pm quartiles, two-sided *p* values were calculated for all test statistics.

469

470

471

472

473


474

475

476

477

478



479

480 **Figure 2. Paired maternal, cord, and infant IgG and neutralization antibodies**

481 A. Paired maternal plasma at delivery (n=19), cord plasma (n=17), and infant follow-up (n=10)

482 by anti-SARS-CoV-2 IgG antibody relative fluorescence units (RFU), (Spearman's rank

483 correlation, dotted line indicates positive cutoff value of 50 RFU). B. Paired maternal plasma at

484 delivery (n=17), cord plasma (n=16), and infant follow-up (n=8) by SARS-CoV-2 label-free
485 surrogate neutralization assay (sVNT), (Spearman's rank correlation, dotted line indicates
486 positive cutoff value of 25). C. Paired cord plasma (n=9) and infant follow-up plasma (n=11)
487 anti-SARS-CoV-2 IgG by weeks of life. D. Paired cord plasma (n=7) and infant follow-up plasma
488 (n=8) label-free surrogate neutralization assay (sVNT) by weeks of life. E. Paired maternal
489 plasma at delivery (n=5), cord plasma (n=5), and paired maternal follow-up (n=5) and infant
490 follow-up plasma (n=5) anti-SARS-CoV-2 IgG. Two-sided p values were calculated for all test
491 statistics.

492

493

494

495

496

497


498

499

500

501

502



503

504 **Figure 3. Neutralization to IgG antibody correlation**

505 A. Maternal plasma at delivery (n=17) B. Cord plasma (n=16) C. Infant follow-up plasma (n=8)

506 SARS-CoV-2 label-free surrogate neutralization assay (sVNT) by anti-SARS-CoV-2 IgG

507 correlation (Spearman's rank correlation). Two-sided p values were calculated for all test

508 statistics.

509

510

511

512

513

514

515

516


517

518

519

520

521



522

523 **Figure 4. Maternal delivery and Cord-to-maternal antibody transfer ratios timing**

524 A. Maternal delivery anti-SARS-CoV-2 IgG antibody transfer ratio by days since vaccine dose 1
 525 (n=19, dashed line indicates positive cutoff >50 RFU) B. Maternal delivery anti-SARS-CoV-2
 526 IgG antibody transfer ratio by gestational age at vaccine dose 1 (n=19, dashed line indicates
 527 positive cutoff >50 RFU) C. Maternal delivery SARS-CoV-2 label-free surrogate neutralization
 528 assay (sVNT) antibody transfer ratio by days since vaccine dose 1 (n=17, dashed line indicates
 529 positive cutoff >25). D. Maternal delivery SARS-CoV-2 label-free surrogate neutralization assay
 530 (sVNT) antibody transfer ratio by gestational age at vaccine dose 1 (n=17, dashed line indicates
 531 positive cutoff >25) E. Cord-to-maternal anti-SARS-CoV-2 IgG antibody transfer ratio by days
 532 since vaccine dose 1 (n=15) F. Cord-to-maternal anti-SARS-CoV-2 IgG antibody transfer ratio
 533 by gestational age at vaccine dose 1 (n=15) G. Cord-to-maternal SARS-CoV-2 label-free
 534 surrogate neutralization assay (sVNT) antibody transfer ratio by days since vaccine dose 1
 535 (n=15). H. Cord-to-maternal SARS-CoV-2 label-free surrogate neutralization assay (sVNT)

536 antibody transfer ratio by gestational age at vaccine dose 1 (n=15). Two-sided p values were
537 calculated for all test statistics.

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556


557

558

559

560

561



562 **Figure 5. PhIP-seq/VirScan paired maternal and cord SARS-CoV-2 Spike protein epitope**
 563 **binding**

564 A. Heatmap displaying results of significant enriched ($p < 0.001$) linear SARS-CoV-2 Spike
 565 protein epitope binding from 15 paired mother-infant dyads in maternal plasma at delivery and
 566 cord plasma by vaccine type and time since vaccine dose 1. Areas of high cumulative epitope

567 binding designated by regions 1-4. B. Cumulative fold enrichment of mothers and infants linear
568 SARS-CoV-2 Spike protein epitope binding.
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592

593 References:

- 594 1 Ellington, S. *et al.* Characteristics of Women of Reproductive Age with Laboratory-
595 Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7,
596 2020. *MMWR Morb Mortal Wkly Rep* **69**, 769-775, doi:10.15585/mmwr.mm6925a1
597 (2020).
- 598 2 Ahlberg, M. *et al.* Association of SARS-CoV-2 Test Status and Pregnancy Outcomes.
599 *Jama*, doi:10.1001/jama.2020.19124 (2020).
- 600 3 Knight, M. *et al.* Characteristics and outcomes of pregnant women admitted to hospital
601 with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *Bmj*
602 **369**, m2107, doi:10.1136/bmj.m2107 (2020).
- 603 4 Martinez-Portilla, R. J. *et al.* Pregnant women with SARS-CoV-2 infection are at higher
604 risk of death and pneumonia: propensity score matched analysis of a nationwide
605 prospective cohort (COV19Mx). *Ultrasound Obstet Gynecol* **57**, 224-231,
606 doi:10.1002/uog.23575 (2021).
- 607 5 CDC. *COVID-19 vaccination among pregnant people aged 18-49 years overall, by*
608 *race/ethnicity, and date reported to CDC - Vaccine Safety Datalink, * United States,*
609 <https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women> (2021).
- 610 6 Gynecologists, A. C. o. O. a. *Statement of Strong Medical Consensus for Vaccination of*
611 *Pregnant Individuals Against COVID-19*, [https://www.acog.org/news/news-](https://www.acog.org/news/news-releases/2021/08/statement-of-strong-medical-consensus-for-vaccination-of-pregnant-individuals-against-covid-19)
612 [releases/2021/08/statement-of-strong-medical-consensus-for-vaccination-of-pregnant-](https://www.acog.org/news/news-releases/2021/08/statement-of-strong-medical-consensus-for-vaccination-of-pregnant-individuals-against-covid-19)
613 [individuals-against-covid-19](https://www.acog.org/news/news-releases/2021/08/statement-of-strong-medical-consensus-for-vaccination-of-pregnant-individuals-against-covid-19)> (2021).

- 614 7 Maykin, M. M., Heuser, C., Feltovich, H. & with the Society for Maternal-Fetal Medicine
615 Health Policy Advocacy, C. Pregnant people deserve the protection offered by SARS-
616 CoV-2 vaccines. *Vaccine* **39**, 171-172, doi:10.1016/j.vaccine.2020.12.007 (2021).
- 617 8 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J*
618 *Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 619 9 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*
620 *Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 621 10 Atyeo, C. *et al.* Compromised SARS-CoV-2-specific placental antibody transfer. *Cell*,
622 doi:10.1016/j.cell.2020.12.027 (2020).
- 623 11 Edlow, A. G. *et al.* Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load,
624 Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the
625 COVID-19 Pandemic. *JAMA Netw Open* **3**, e2030455,
626 doi:10.1001/jamanetworkopen.2020.30455 (2020).
- 627 12 Flannery, D. D. *et al.* Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2
628 Antibodies and Placental Transfer Ratios. *JAMA Pediatr*,
629 doi:10.1001/jamapediatrics.2021.0038 (2021).
- 630 13 Atyeo, C. *et al.* Compromised SARS-CoV-2-specific placental antibody transfer. *Cell* **184**,
631 628-642.e610, doi:10.1016/j.cell.2020.12.027 (2021).
- 632 14 Gray, K. J. *et al.* Coronavirus disease 2019 vaccine response in pregnant and lactating
633 women: a cohort study. *Am J Obstet Gynecol* **225**, 303.e301-303.e317,
634 doi:10.1016/j.ajog.2021.03.023 (2021).
- 635 15 Nir, O. *et al.* Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies
636 among parturient women treated with BNT162b2 messenger RNA vaccine during

- 637 pregnancy. *Am J Obstet Gynecol MFM* **4**, 100492, doi:10.1016/j.ajogmf.2021.100492
638 (2021).
- 639 16 Song, D. *et al.* Passive and active immunity in infants born to mothers with SARS-CoV-2
640 infection during pregnancy: prospective cohort study. *BMJ Open* **11**, e053036,
641 doi:10.1136/bmjopen-2021-053036 (2021).
- 642 17 Atyeo, C. *et al.* COVID-19 mRNA vaccines drive differential antibody Fc-functional
643 profiles in pregnant, lactating, and non-pregnant women. *Sci Transl Med*, eabi8631,
644 doi:10.1126/scitranslmed.abi8631 (2021).
- 645 18 Zamecnik, C. R. *et al.* ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for
646 SARS-CoV-2 Antigens. *Cell Rep Med* **1**, 100123, doi:10.1016/j.xcrm.2020.100123 (2020).
- 647 19 Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and
648 correlates of severity. *Science* **370**, doi:10.1126/science.abd4250 (2020).
- 649 20 Li, Y. *et al.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in
650 COVID-19 patients. *Cell Mol Immunol* **17**, 1095-1097, doi:10.1038/s41423-020-00523-5
651 (2020).
- 652 21 Fenizia, C. *et al.* Analysis of SARS-CoV-2 vertical transmission during pregnancy. *Nat*
653 *Commun* **11**, 5128, doi:10.1038/s41467-020-18933-4 (2020).
- 654 22 Zeng, H. *et al.* Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *JAMA*
655 **323**, 1848-1849, doi:10.1001/jama.2020.4861 (2020).
- 656 23 Zeng, L. *et al.* Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to
657 Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr* **174**, 722-725,
658 doi:10.1001/jamapediatrics.2020.0878 (2020).

- 659 24 Healy, C. M. *et al.* Kinetics of maternal pertussis-specific antibodies in infants of mothers
660 vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.
661 *Vaccine* **38**, 5955-5961, doi:10.1016/j.vaccine.2020.06.050 (2020).
- 662 25 Sissoko, M. S. *et al.* Safety and efficacy of PfSPZ Vaccine against *Plasmodium falciparum*
663 via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised,
664 double-blind phase 1 trial. *The Lancet Infectious Diseases* **17**, 498-509,
665 doi:10.1016/s1473-3099(17)30104-4 (2017).
- 666 26 Leuridan, E., Hens, N., Hutse, V., Aerts, M. & Van Damme, P. Kinetics of maternal
667 antibodies against rubella and varicella in infants. *Vaccine* **29**, 2222-2226,
668 doi:10.1016/j.vaccine.2010.06.004 (2011).
- 669 27 Pyzik, M. *et al.* The Neonatal Fc Receptor (FcRn): A Misnomer? *Front Immunol* **10**, 1540,
670 doi:10.3389/fimmu.2019.01540 (2019).
- 671 28 Luo, Y. R., Yun, C., Chakraborty, I., Wu, A. H. B. & Lynch, K. L. A SARS-CoV-2 Label-Free
672 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics
673 in COVID-19 Patients. *J Clin Microbiol* **59**, e0019321, doi:10.1128/jcm.00193-21 (2021).
- 674 29 Firan, M. *et al.* The MHC class I-related receptor, FcRn, plays an essential role in the
675 maternofetal transfer of gamma-globulin in humans. *Int Immunol* **13**, 993-1002,
676 doi:10.1093/intimm/13.8.993 (2001).
- 677 30 Williams, P. J. *et al.* Short communication: selective placental transport of maternal IgG
678 to the fetus. *Placenta* **16**, 749-756, doi:10.1016/0143-4004(95)90018-7 (1995).
- 679 31 Kibe, T. *et al.* Glycosylation and Placental Transport of Immunoglobulin G. *Journal of*
680 *Clinical Biochemistry and Nutrition* **21**, 57-63 (1996).

- 681 32 Borghi, S. *et al.* FcRn, but not FcγRs, drives maternal-fetal transplacental transport of
682 human IgG antibodies. *Proc Natl Acad Sci U S A* **117**, 12943-12951,
683 doi:10.1073/pnas.2004325117 (2020).
- 684 33 Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG
685 placental transfer in healthy and pathological pregnancies. *Clin Dev Immunol* **2012**,
686 985646, doi:10.1155/2012/985646 (2012).
- 687 34 Clements, T. *et al.* Update on Transplacental Transfer of IgG Subclasses: Impact of
688 Maternal and Fetal Factors. *Front Immunol* **11**, 1920, doi:10.3389/fimmu.2020.01920
689 (2020).
- 690 35 Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike
691 protein of SARS-CoV-2. *Science* **369**, 650-655, doi:10.1126/science.abc6952 (2020).
- 692 36 Golan, Y. *et al.* Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273
693 Vaccines in Human Milk. *JAMA Pediatr* **175**, 1069-1071,
694 doi:10.1001/jamapediatrics.2021.1929 (2021).
695